In particular, the Phase II study (NCT04291105) assesses the safety and efficacy of VSV-IFNB-hNIS in combination with cemiplimab (an anti-PD1 antibody that has been shown to be effective in the treatment of cutaneous squamous cell carcinoma) [177], with IV vs. IT administration for melanoma treatment, and with IV infusion for hepatocellular carcinoma, non-small cell lung cancer (NSCLC) and endometrial cancer treatment. Here, IFNB1 is linked to hepatocellular carcinoma.